There are now several experimental treatments vying to be tested, but each must be greenlit by national regulatory authorities whenever and wherever an outbreak occurs. There remain deeply divergent positions among scientists about how to design outbreak trials, specifically whether studies that don’t compare treatments to placebos can generate useful data

Quick Read

The rise of spit kits is leaving consumers with lots of data and few answers. Genetic counselors could help people understand these results, but there aren’t enough of them to go around

Quick Read

Q&A featuring comments from our Juli Murphy Bollinger

Quick Read

In February 2016, the FDA recommended that collection of donated blood cease in areas in the United States in which ZIKV was active, unless blood testing or pathogen-reduction methods could be implemented. At the time, no vectorborne cases of ZIKV infection had been reported in the continental United States; however, an epidemic was under way in the U.S. territories, most notably in Puerto Rico and the U.S. Virgin Islands

Quick Read

An expensive screening program designed to keep the Zika virus out of the Red Cross’ blood supply has caught fewer than a dozen infected donations, a new study published Wednesday revealed. Study authors include our Jeremy Sugarman

Quick Read

Vulnerable groups, such as children, prisoners and people with limited mental capacity, are usually excluded from drug trials. And, until quite recently, it was considered unethical to test drugs on pregnant women, too… But the tide is turning

Quick Read

A pair of neuroscientists are working with Major League Baseball to help measure the mental aspects of a batter’s swing

Quick Read

Legislation on the testing of self-driving cars does not address liability and safety concerns, warn Ashley Nunes, Bryan Reimer and Joseph F. Coughlin

Quick Read